Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $1.77 in the prior trading day, Standard BioTools Inc (NASDAQ: LAB) closed at $1.88, up 6.21%. In other words, the price has increased by $6.21 from its previous closing price. On the day, 1.61 million shares were traded. LAB stock price reached its highest trading level at $1.885 during the session, while it also had its lowest trading level at $1.73.
Ratios:
Our goal is to gain a better understanding of LAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.
On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 12 ’24 when Black Jeffrey G. bought 57,971 shares for $2.12 per share.
Taich Adam bought 45,851 shares of LAB for $91,725 on Sep 09 ’24. On Aug 27 ’24, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 250,000 shares for $2.19 each. As a result, the insider paid 546,750 and bolstered with 54,025,821 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 699846912 and an Enterprise Value of 227302752. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.49 while its Price-to-Book (P/B) ratio in mrq is 1.43. Its current Enterprise Value per Revenue stands at 1.458 whereas that against EBITDA is -1.988.
Stock Price History:
The Beta on a monthly basis for LAB is 1.58, which has changed by -0.24358976 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $3.04, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is 1.13%, while the 200-Day Moving Average is calculated to be -8.84%.
Shares Statistics:
The stock has traded on average 1.97M shares per day over the past 3-months and 2112670 shares per day over the last 10 days, according to various share statistics. A total of 372.26M shares are outstanding, with a floating share count of 360.48M. Insiders hold about 3.16% of the company’s shares, while institutions hold 75.19% stake in the company. Shares short for LAB as of 1735603200 were 13523264 with a Short Ratio of 6.87, compared to 1732838400 on 13767237. Therefore, it implies a Short% of Shares Outstanding of 13523264 and a Short% of Float of 7.46.
Earnings Estimates
The firm’s stock currently is rated by 2.0 analysts. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.19 and -$0.24 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$0.16, with 2.0 analysts recommending between -$0.15 and -$0.16.
Revenue Estimates
3 analysts predict $43.03M in revenue for the current quarter. It ranges from a high estimate of $44.6M to a low estimate of $42.2M. As of the current estimate, Standard BioTools Inc’s year-ago sales were $28.19MFor the next quarter, 3 analysts are estimating revenue of $45.6M. There is a high estimate of $48.1M for the next quarter, whereas the lowest estimate is $43.1M.
A total of 3 analysts have provided revenue estimates for LAB’s current fiscal year. The highest revenue estimate was $173M, while the lowest revenue estimate was $170M, resulting in an average revenue estimate of $171.2M. In the same quarter a year ago, actual revenue was $106.34MBased on 3 analysts’ estimates, the company’s revenue will be $186.93M in the next fiscal year. The high estimate is $195M and the low estimate is $180.8M.
